scispace - formally typeset
B

Bulent Ozpolat

Researcher at University of Texas Health Science Center at Houston

Publications -  15
Citations -  8289

Bulent Ozpolat is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Cancer & Immune system. The author has an hindex of 8, co-authored 15 publications receiving 7644 citations. Previous affiliations of Bulent Ozpolat include University of Texas MD Anderson Cancer Center.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes

Daniel J. Klionsky, +235 more
- 16 Feb 2008 - 
TL;DR: A set of guidelines for the selection and interpretation of the methods that can be used by investigators who are attempting to examine macroautophagy and related processes, as well as by reviewers who need to provide realistic and reasonable critiques of papers that investigate these processes are presented.
Journal ArticleDOI

Paraneoplastic Thrombocytosis in Ovarian Cancer

Rebecca L. Stone, +33 more
- 16 Feb 2012 - 
TL;DR: Findings support the existence of a paracrine circuit wherein increased production of thrombopoietic cytokines in tumor and host tissue leads to paraneoplasticThrombocytosis, which fuels tumor growth.
Journal ArticleDOI

DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.

L. B. Lachman, +5 more
- 01 Apr 2001 - 
TL;DR: Preclinical data indicate that therapeutic vaccination of patients with ELVIS-neu may reduce metastasis from HER2/neu-expressing breast and ovarian tumors.
Journal ArticleDOI

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.

Cristian Rodriguez-Aguayo, +17 more
- 01 Feb 2019 - 
TL;DR: These findings identify PTGER3 as a potential therapeutic target in chemoresistant ovarian cancers expressing high levels of this oncogenic protein.